Ligand Pharmaceuticals Reports the Acquisition of APEIRON Biologics for $100M


Ligand has agreed to acquire APEIRON, along with its royalty rights to Qarziba for high-risk neuroblastoma. APEIRON gets an undisclosed royalty on Qarziba sales outside mainland China from Recordati & within mainland China from BeiGene
The company will acquire APEIRON for $100M in cash with APEIRON shareholders receiving additional consideration for future commercial & regulatory milestones plus ~$28M if Qarziba royalties exceed specific target by either 2030 or 2034
Ligand will also invest ~$4M in invIOs Holding (spin-off of APEIRON) to fund the development of early-stage immuno-oncology candidates, for which APEIRON will get royalties & milestones. The transaction is anticipated to conclude in Jul 2024

Ref: Ligand | Image: Ligand

Related News:- Novartis to Acquire Mariana Oncology, Expanding its Radioligand Therapy Pipeline

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at